Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $3.7 million.

  • SAB Biotherapeutics' Accumulated Expenses rose 1119.53% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 1119.53%. This contributed to the annual value of $4.2 million for FY2024, which is 2264.72% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Accumulated Expenses of $3.7 million as of Q3 2025, which was up 1119.53% from $5.1 million recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Accumulated Expenses peaked at $5.1 million during Q2 2025, and registered a low of $80000.0 during Q1 2021.
  • Its 5-year average for Accumulated Expenses is $1.8 million, with a median of $678855.0 in 2022.
  • Within the past 5 years, the most significant YoY rise in SAB Biotherapeutics' Accumulated Expenses was 74856.87% (2022), while the steepest drop was 2415.46% (2022).
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Accumulated Expenses stood at $674858.0 in 2021, then fell by 24.15% to $511849.0 in 2022, then skyrocketed by 564.32% to $3.4 million in 2023, then grew by 22.65% to $4.2 million in 2024, then decreased by 11.12% to $3.7 million in 2025.
  • Its Accumulated Expenses stands at $3.7 million for Q3 2025, versus $5.1 million for Q2 2025 and $4.0 million for Q1 2025.